A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants
A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants
Not yet recruiting · NCT07549750 · Registry updated 2026-04-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Not yet recruiting | Phase 1 | 2026-04-24 | NCT07549750 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Helixon Biotechnology (Suzhou) Co., Ltd | 6 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Veritus Research | Bayswater | Australia | 15 |